Kanis JA, Cooper C, Rizzoli R, Reginster J-Y, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF) (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3–44

Article  CAS  PubMed  Google Scholar 

Kanis JA, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, McCloskey EV, Willers C, Borgström F (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 16:82

Article  PubMed  PubMed Central  Google Scholar 

Singer A, Exuzides A, Spangler L, O’Malley C, Colby C, Johnston K, Agodoa I, Baker J, Kagan RR (2015) Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. Mayo Clin Proc 90:53–62

Article  PubMed  Google Scholar 

International Diabetes Federation (2025) IDF diabetes atlas 11th edition—2025. IDF_Diabetes_Atlas_11th_Edition_2025_WEB.pdf. P45. Accessed 15 Oct 2025

Dong B, Lv R, Wang J, Che L, Wang Z, Huai Z, Wang Y, Xu L (2022) The extraglycemic effect of SGLT-2is on mineral and bone metabolism and bone fracture. Front Endocrinol 13:918350

Article  Google Scholar 

Ye Y, Zhao C, Liang J, Yang Y, Yu M, Qu X (2019) Effect of sodium-glucose co-transporter 2 inhibitors on bone metabolism and fracture risk. Front Pharmacol 9:1517

Article  PubMed  PubMed Central  Google Scholar 

Bilezikian JP, Watts NB, Usiskin K, Polidori D, Fung A, Sullivan D, Rosenthal N (2016) Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J Clin Endocrinol Metab 101:44–51

Article  CAS  PubMed  Google Scholar 

Gallo S, Charbonnel B, Goldman A, Shi H, Huyck S, Darekar A, Lauring B, Terra SG (2019) Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial. Diabetes Obes Metab 21:1027–1036

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hauner H (2002) The mode of action of thiazolidinediones. Diabetes Metab Res Rev 18:S10–15

Article  Google Scholar 

Grey A (2009) Thiazolidinedione-induced skeletal fragility–mechanisms and implications. Diabetes Obes Metab 11:275–284

Article  CAS  PubMed  Google Scholar 

Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, Reid IR (2007) The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 92:1305–1310

Article  CAS  PubMed  Google Scholar 

Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, Strotmeyer ES, Resnick HE, Carbone L, Beamer BA, Park SW, Lane NE, Harris TB, Cummings SR (2006) Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91:3349–3354

Article  CAS  PubMed  PubMed Central  Google Scholar 

Billington EO, Grey A, Bolland MJ (2015) The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis. Diabetologia 58:2238–2246

Article  CAS  PubMed  Google Scholar 

HIRA Bigdata Open Portal (2024) Medical statistics information. https://opendata.hira.or.kr/op/opc/olap3thDsInfoTab2.do. Accessed 26 Dec 2024

Song E, Park E, Choe SA, Park J, Song BM, Han K, Park HY (2023) How do Korean women manage menstrual or menopausal symptoms: 2022 women’s health survey for sexual and reproductive health. Public Health Weekly Rep 16:783–800

Google Scholar 

Kim K, Kim JA, Kim S (2014) A guide for the utilization of health insurance review and assessment service national patient samples. Epidemiol Health 36:e2014008

Article  PubMed  PubMed Central  Google Scholar 

Health Insurance Review & Assessment Service (2025) HIRA research data user guide. file:///C:/Users/admin/Downloads/%EC%97%B0%EA%B5%AC%EA%B3%BC%EC%A0%9C%20%EC%9D%B4%EC%9A%A9%20%EA%B0%80%EC%9D%B4%EB%93%9C%20(11).pdf. Accessed 9 Apr 2025

Wikarek A, Grabarczyk M, Klimek K, Janoska-Gawrońska A, Suchodolska M, Holecki M (2024) Effect of drugs used in pharmacotherapy of type 2 diabetes on bone density and risk of bone fractures. Medicina Kaunas 60:393

Article  PubMed  PubMed Central  Google Scholar 

Tamaki J, Ogawa S, Fujimori K, Ishii S, Nakatoh S, Okimoto N, Kamiya K, Iki M (2023) Hip and vertebral fracture risk after initiating antidiabetic drugs in Japanese elderly: a nationwide study. J Bone Miner Metab 41:29–40

Article  CAS  PubMed  Google Scholar 

Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM, Sundararajan V (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173:676–682

Article  PubMed  Google Scholar 

The Korean Society for Bone and Mineral Research (2024) 2024 Guidelines for the diagnosis and management of osteoporosis. https://www.ksbmr.org/bbs/?number=1672&mode=view&code=notice. Accessed 26 Dec 2024

Kurth T, Walker AM, Glynn RJ, Chan KA, Gaziano JM, Berger K, Robins JM (2006) Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 163:262–270

Article  PubMed  Google Scholar 

Ha J, Lim Y, Kim MK, Kwon HS, Song KH, Ko SH, Kang MI, Moon SD, Baek KH (2021) Comparison of the effects of various antidiabetic medication on bone mineral density in patients with type 2 diabetes mellitus. Endocrinol Metab 36:895–903

Article  CAS  Google Scholar 

Korean Diabetes Association (2025) Diabetes fact sheet in Korea 2024. https://www.diabetes.or.kr/bbs/?code=fact_sheet&mode=view&number=2792&page=1&code=fact_sheet. Accessed 11 Mar 2025

American Diabetes Association Professional Practice Committee (2025) 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes—2025. Diabetes Care 48:S181–S206

Article  Google Scholar 

American Diabetes Association Professional Practice Committee (2025) Comprehensive medical evaluation and assessment of comorbidities: Standards of care in diabetes–2025. Diabetes Care 48:S59–S85

Article  Google Scholar 

Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, Harris ST, Hurley DL, Kelly J, Lewiecki EM, Pessah-Pollack R, McClung M, Wimalawansa SJ, Watts NB (2020) American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis–2020 update. Endocr Pract 26:1–46

Article  PubMed  Google Scholar 

Das T, Biswas MAAJ, Mondal P, Sarker S, Lim HJJ (2024) Osteoporosis incidence and its associated factors in the older Korean population: findings from a population-based cohort study. Arch Osteoporos 19:111

Article  PubMed  Google Scholar 

Weitzmann MN, Pacifici R (2006) Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 116:1186–1194

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bultink IEM, Lems WF (2013) Osteoarthritis and osteoporosis: what is the overlap? Curr Rheumatol Rep 15:328

Article  PubMed  Google Scholar 

Adami G, Saag KG (2019) Osteoporosis pathophysiology, epidemiology, and screening in rheumatoid arthritis. Curr Rheumatol Rep 21:34

Article  PubMed  Google Scholar 

Park DH, Seo SI, Lee KJ, Kim J, Kim Y, Seo WW, Lee HS, Shin WG, Yoo JJ (2022) Long-term proton pump inhibitor use and risk of osteoporosis and hip fractures: a nationwide population-based and multicenter cohort study using a common data model. J Gastroenterol Hepatol 37:1534–1543

Article  CAS  PubMed  Google Scholar 

Oh TJ, Moon J-Y, Hur KY, Ko SH, Kim HJ, Kim T, Lee DW, Moon MK, Committee of Clinical Practice Guideline, Korean Diabetes Association and Committee of the Cooperative Studies, Korean Society of Nephrology (2020) Sodium-glucose cotransporter-2 inhibitor for renal function preservation in patients with type 2 diabetes mellitus: a Korean Diabetes Association and Korean Society of Nephrology consensus statement. Kidney Res Clin Pract 39:269–283

Article  PubMed  PubMed Central  Google Scholar 

Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, Evans RM (2013) PPARγ signaling and metabolism: the good, the bad and the future. Nat Med 19:557–566

Article  CAS  PubMed  PubMed Central  Google Scholar